2448-9190 2448-9190 S2448-91902023000400297 10.29262/ram.v70i4.1340 Chile Perú 00 12 2023 00 12 2023 70 4 297 299

1 2003 348 11 11 986-93 2 2012 130 5 5 1123-9 3 2013 132 6 6 1368-74 4 2018 3 85-94 5 2018 48 7 7 825-36 6 2019 72 2 2 673-4 7 2020 158 1 1 111-22 8 Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of dupilumab as adjunct to AR101 (Peanut Oral Immunotherapy). ClinicalTrials.gov Identifier: NCT03682770 9 Study to evaluate dupilumab monotherapy in pediatric patients with peanut allergy. ClinicalTrials.gov Identifier:NCT03793608. 10 2018 13 1 1 171-9 11 2019 4 22 22 12 2006 118 6 6 1312-219